GC 3106A
Alternative Names: GC 3106; GC3106ALatest Information Update: 01 Apr 2022
At a glance
- Originator Green Cross
- Developer GC Pharma
- Class Influenza virus vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Influenza virus infections
Most Recent Events
- 29 Mar 2022 GC Pharma is now called GC Biopharma
- 28 Sep 2021 No development reported - Phase-III for Influenza virus infections (Prevention, In volunteers) in South Korea (IM)
- 20 Feb 2019 GC 3106A is still in phase III trials for Influenza virus infections (Prevention, In volunteers) in South Korea (GC Pharma pipeline, February 2019)